LT2573166T - T ląstelių paruošimo būdas ląstelių terapijai - Google Patents

T ląstelių paruošimo būdas ląstelių terapijai

Info

Publication number
LT2573166T
LT2573166T LTEP12177732.0T LT12177732T LT2573166T LT 2573166 T LT2573166 T LT 2573166T LT 12177732 T LT12177732 T LT 12177732T LT 2573166 T LT2573166 T LT 2573166T
Authority
LT
Lithuania
Prior art keywords
cells
preparing
methods
cell therapy
therapy
Prior art date
Application number
LTEP12177732.0T
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of LT2573166T publication Critical patent/LT2573166T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
LTEP12177732.0T 2004-02-26 2005-02-24 T ląstelių paruošimo būdas ląstelių terapijai LT2573166T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54796604P 2004-02-26 2004-02-26

Publications (1)

Publication Number Publication Date
LT2573166T true LT2573166T (lt) 2016-09-26

Family

ID=34910966

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12177732.0T LT2573166T (lt) 2004-02-26 2005-02-24 T ląstelių paruošimo būdas ląstelių terapijai

Country Status (14)

Country Link
US (6) US7678572B2 (lt)
EP (3) EP2573166B1 (lt)
JP (5) JP2007525225A (lt)
CA (1) CA2555714C (lt)
CY (1) CY1117750T1 (lt)
DK (1) DK2573166T3 (lt)
ES (1) ES2586295T3 (lt)
HU (1) HUE028467T2 (lt)
IL (1) IL177404A (lt)
LT (1) LT2573166T (lt)
PL (1) PL2573166T3 (lt)
PT (1) PT2573166T (lt)
SI (1) SI2573166T1 (lt)
WO (1) WO2005081982A2 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US7678572B2 (en) 2004-02-26 2010-03-16 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
PL1749090T3 (pl) * 2004-03-01 2017-12-29 Immunovative Therapies, Ltd. Sposób formułowania i kompozycja do terapii komórkowej
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
HUE036094T2 (hu) * 2010-08-20 2018-06-28 Immunovative Therapies Ltd Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek
CN109876138A (zh) 2011-05-03 2019-06-14 免疫创新治疗有限公司 利用免疫疗法诱导il-12
JP5934783B2 (ja) 2011-05-03 2016-06-15 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
EP3004320A4 (en) 2013-06-24 2017-05-17 Wilson Wolf Manufacturing Corporation Closed system device and methods for gas permeable cell culture process
CN103525763A (zh) * 2013-09-28 2014-01-22 青岛麦迪赛斯生物科技有限公司 一种高效cik细胞的培养方法
AU2015204770B2 (en) 2014-01-08 2020-07-02 Immunovative Therapies, Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017106453A1 (en) * 2015-12-17 2017-06-22 University Of Maryland, Baltimore County A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
SG11201808022WA (en) * 2016-03-17 2018-10-30 Berkeley Lights Inc Selection and cloning of t lymphocytes in a microfluidic device
JP6987080B2 (ja) 2016-05-05 2021-12-22 サウスウェスト リサーチ インスティテュート 細胞増殖のための三次元バイオリアクター及び関連用途
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
EP3856888A4 (en) 2018-09-24 2022-10-12 Southwest Research Institute THREE-DIMENSIONAL BIOREACTORS

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US4279248A (en) * 1979-07-20 1981-07-21 Shlomo Gabbay Sternum closure device and procedure for using same
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
ZA888978B (en) 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
AU684461B2 (en) * 1992-04-07 1997-12-18 Regents Of The University Of Michigan, The CD28 pathway immunoregulation
JP3355666B2 (ja) * 1992-10-22 2002-12-09 ソニー株式会社 変調回路
WO1994012196A1 (en) * 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
DK0700430T3 (da) * 1993-06-04 2005-08-15 Us Navy Fremgangsmåder til selektivt af stimulere proliferation af T-celler
AU7478394A (en) 1993-08-06 1995-02-28 Cytel Corporation Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
EP0764203A1 (en) * 1994-06-03 1997-03-26 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
JP2002516562A (ja) 1996-03-04 2002-06-04 ターゲティッド ジェネティックス コーポレイション Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」）
JP5006998B2 (ja) 1996-05-23 2012-08-22 ザ スクリプス リサーチ インスティチュート Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４＋ｔ細胞の活性化方法
AU5596898A (en) 1996-12-03 1998-06-29 Osteobiologics, Inc. Biodegradable polymeric film
AU738538B2 (en) 1997-01-31 2001-09-20 Hemosol Inc. Method for the production of selected lymphocytes
DE69840171D1 (de) 1997-05-30 2008-12-11 Osteobiologics Inc Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung
EP1030674A1 (en) 1997-11-10 2000-08-30 Arch Development Corporation METHODS FOR TREATMENT OF TUMORS AND TUMOR CELLS USING $i(EX VIVO) ACTIVATED T CELLS
AU772316B2 (en) * 1999-01-29 2004-04-22 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
JP2001054563A (ja) 1999-07-12 2001-02-27 Isotis Bv 縫合糸
AU3327701A (en) * 2000-02-03 2001-08-14 Millennium Pharm Inc Humanized anti-ccr2 antibodies and methods of use therefor
CN1227265C (zh) * 2000-02-09 2005-11-16 人类基因组科学公司 抗ccr5的抗体
US6867041B2 (en) * 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA02008265A (es) 2000-02-24 2004-09-10 Xcyte Therapies Inc Concentracion y estimulacion simultanea de calulas.
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20020127208A1 (en) * 2000-08-31 2002-09-12 Waller Edmund K. Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
AU2002342299A1 (en) 2001-10-31 2003-05-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Generation of use of tc1 and tc2 cells
WO2003053216A2 (en) 2001-12-06 2003-07-03 University Of Washington Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
JP5068931B2 (ja) 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US7678572B2 (en) * 2004-02-26 2010-03-16 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
PL1749090T3 (pl) 2004-03-01 2017-12-29 Immunovative Therapies, Ltd. Sposób formułowania i kompozycja do terapii komórkowej
EP1744794A2 (en) 2004-03-05 2007-01-24 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair

Also Published As

Publication number Publication date
PT2573166T (pt) 2016-07-07
PL2573166T3 (pl) 2016-11-30
JP2015129184A (ja) 2015-07-16
US20110177596A1 (en) 2011-07-21
JP2014042529A (ja) 2014-03-13
CA2555714C (en) 2013-12-03
JP2017093468A (ja) 2017-06-01
US8883974B2 (en) 2014-11-11
EP2573166B1 (en) 2016-05-11
JP2011072319A (ja) 2011-04-14
DK2573166T3 (da) 2016-07-04
WO2005081982A3 (en) 2007-01-25
US7678572B2 (en) 2010-03-16
US8313944B2 (en) 2012-11-20
EP1776583A4 (en) 2009-04-29
ES2586295T3 (es) 2016-10-13
IL177404A0 (en) 2007-07-04
US20050191291A1 (en) 2005-09-01
EP2573166A3 (en) 2013-05-29
SI2573166T1 (sl) 2016-09-30
US8071374B2 (en) 2011-12-06
US9593308B2 (en) 2017-03-14
EP2573166A2 (en) 2013-03-27
EP1776583A2 (en) 2007-04-25
US7956164B2 (en) 2011-06-07
EP3067415A1 (en) 2016-09-14
US20150024489A1 (en) 2015-01-22
CY1117750T1 (el) 2017-05-17
IL177404A (en) 2016-12-29
JP6031021B2 (ja) 2016-11-24
JP2007525225A (ja) 2007-09-06
US20100113753A1 (en) 2010-05-06
HUE028467T2 (en) 2016-12-28
US20110281357A1 (en) 2011-11-17
CA2555714A1 (en) 2005-09-09
WO2005081982A2 (en) 2005-09-09
US20100255043A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
LT2573166T (lt) T ląstelių paruošimo būdas ląstelių terapijai
GB2411178A8 (en) Apparatus for culturing cells
EP1815244A4 (en) DEVICE FOR CULTURING CELLS
PT2266544T (pt) Método para introdução de substâncias terapêuticas em células
EP1729798A4 (en) THERAPY USING ANTIGEN-SPECIFIC T LYMPHOCYTES
GB2418305B (en) Charger
IL183091A0 (en) Method for preparing n-phenylpyrazole-1-carboxyamides
EP1769066A4 (en) MODIFIED ANTIGEN PRESENTATION CELLS
TWI316307B (en) Case for batteries and preparation method thereof
IL184262A (en) A method for culturing cells in culture
ZAA200500371S (en) Battery
GB2404665B (en) Cell culture
EP1820852A4 (en) HUMAN SERUM FOR CELL CULTURE
EP1820847A4 (en) COMPOSITION FOR COOLANT STORAGE OF CELLS
ZA200703293B (en) Cell bandage
ZA200506732B (en) Cell culture
EP1776182A4 (en) APPARATUS FOR ENCAPSULATING CELLS
EP1807508A4 (en) METHODS FOR PREPARING CELLS AND VIRUSES
ZA200704058B (en) Methods for producing mammalian cells
EP1725652A4 (en) CULTURE PROCESSES OF CRYPTOSPORIDIUM
GB2418056B (en) Battery
GB2409897B (en) Spectroscopy cell
GB0401766D0 (en) Phoretic cell
EP1871872A4 (en) METHOD FOR ACTIVATING CD8 T LYMPHOCYTES
GB0421753D0 (en) Cell line